In the present study, we tested the hypothesis that uptitrating the dose of an angiotensin receptor blocker (ARB) is superior to combined treatment with an ARB and a calcium channel blocker for the same degree of blood pressure (BP) reduction, with respect to urinary albumin excretion in diabetic patients treated with a standard dose of the ARB. Hypertensive patients with type 2 diabetes mellitus and albuminuria (X30 mg g À1 creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy. After a 12-week run-in period, baseline evaluations were performed and patients with BP X130/80 mm Hg were randomly assigned to receive either candesartan (12 mg per day) or candesartan (8 mg per day) plus amlodipine (2.5 mg per day) for a further 12 weeks. The primary endpoint was a reduction in urinary albumin levels. Although there was no significant difference in the BP reduction between the two groups, the reduction in urinary albumin was greater in the up-titrated than the combination therapy group (À40 ± 14% vs À9 ± 38%, respectively; Po0.0001). Thus, up-titration of candesartan more effectively reduces urinary albumin excretion than combined candesartan plus amlodipine in hypertensive patients with diabetes for the same degree of BP reduction.
Introduction
Hypertensive patients with diabetes mellitus are at extremely high risk of serious adverse outcomes, including renal failure, early development of cardiovascular disease and premature death. 1 The kidney is one of the most important target organs of hypertension and diabetes, and microalbuminuria is an early indicator of nephropathy. [2] [3] [4] However, recent studies have revealed that albuminuria is not only a marker of organ damage, but also a predictor of cardiovascular events in both non-diabetic and diabetic populations. [5] [6] [7] [8] [9] There is a linear relationship between the risk of cardiovascular morbidity and mortality and urinary albumin excretion, without any recognisable threshold or plateau. [9] [10] [11] Thus, every effort is made to reduce urinary albumin excretion in the management of diabetic and hypertensive patients with albuminuria. Indeed, a reduction in albuminuria following anti-hypertensive treatment may lead to a reduction in cardiovascular events. 12 Although angiotensin receptor blockers (ARBs) have been shown to be renoprotective in diabetic nephropathy, [13] [14] [15] strict blood pressure (BP) control is also essential to reduce and prevent the progression of albuminuria. However, effective BP control is particularly difficult to achieve in patients with diabetes mellitus, 16 and target BP levels are seldom achieved with standard doses of renin-angiotensin system (RAS) inhibitors. 16, 17 Calcium channel blockers are frequently used in combination with RAS inhibitors because they reduce BP even in patients who are resistant to anti-hypertensive medications. 18 However, the renoprotective effect of calcium channel blockers is contentious. [19] [20] [21] [22] Conversely, the up-titration of doses of ARBs is likely to bring about beneficial results because of the protective effects of these drugs on the kidney, as supported by considerable evidence in the literature. Thus, the aim of the present study was to generate a hypothesis that up-titrating the dose of an ARB would be superior to combined treatment with an ARB plus a calcium channel blocker, with respect to renal protection for the same level of BP achieved and the same degree of BP reduction in patients, with albuminuria being treated with a standard dose of an ARB.
Subjects and methods
The present study was a multicentre, prospective, randomized, open and blinded end-point trial to assess the renoprotective effects of titrating the dose of an ARB, namely candesartan, and combined ARB plus calcium channel blocker treatment in patients with albuminuria being treated with a standard dose of the ARB. The study was performed in accordance with the principles of the Declaration of Helsinki, and was approved by the Ethics Committee of Komono Kosei Hospital. All patients provided written informed consent before participating in the study. The core study centre was located at Komono Kosei Hospital, which was responsible for data collection, safety and event monitoring and statistical analysis. The recruitment and follow-up of patients were undertaken by investigators in each of the participating hospitals.
Patients
Patients were recruited to the study between August 2007 and September 2009. Patients were eligible for inclusion in the study if (1) they had essential hypertension and type 2 diabetes mellitus (T2DM); (2) they were between 20 and 70 years of age; (3) they had albuminuria (X30 mg g À1 creatinine); and (4) had systolic BP (SBP) X140 mm Hg and/or diastolic BP (DBP) X90 mm Hg when not receiving treatment for their hypertension or SBPX130 mm Hg and/or DBPX80 mm Hg while receiving anti-hypertensive treatment, with a standard dose of a single class of anti-hypertensive drug. The diagnosis of T2DM was based on World Health Organization criteria. 23 All patients with a previous diagnosis of diabetes mellitus were treated with oral anti-diabetic medications. Secondary hypertension was excluded based on medical history and appropriate physical, biochemical and radiological examinations. BP was measured by a doctor after patients had been seated for 2 min with their back supported and their arms supported at heart level. Proper cuff size was determined based on arm circumference. Systolic and DBP levels were recorded as the first and fifth Korotkoff phases, respectively, using a mercury sphygmomanometer. Three consecutive BP measurements were taken at 2-min intervals and the mean of the second and third measurements was recorded as the BP for the patient.
Exclusion criteria for the study included secondary hypertension, a recent (within the previous 6 months) history of myocardial infarction, heart failure, angina pectoris or stroke, uncontrolled diabetes mellitus (HbA1cX9.0%), a disorder that required treatment with calcium channel blockers, serum creatinine levels in men and women of X1.5 and X1.2 mg dl
À1
, respectively, pregnancy, serum potassium X5.5 mEq l À1 and clinical SBP4180 mm Hg and/or DBP4110 mm Hg.
Procedures
After written informed consent had been obtained, patients entered an open-label run-in period during which they received candesartan (8 mg, once daily) monotherapy for 12 weeks ( Figure 1 ). All patients receiving anti-hypertensive medication were switched to candesartan, with all other anti-hypertensive medications withdrawn. At the end of the run-in period, baseline evaluations were performed and only patients with SBPX130 mm Hg and/or DBPX80 mm Hg were used in the next phase of the study. Of the original 60 patients enroled in the study, two (3.3%) were excluded at the end of the run-in period. The remaining patients were randomly assigned to receive either candesartan (12 mg per day; up-titration group; n ¼ 29) or candesartan (8 mg per day) in combination with amlodipine (2.5 mg per day; combination group; n ¼ 29) for a further 12 weeks, with regular visits every 4 weeks for the duration of the study. If BP did not reach the target of 130/80 mm Hg at any visit, amlodipine or diuretics were further prescribed to the patients. The primary end-point of the study was a reduction in urinary albumin excretion. Secondary end-points included changes in BP, serum creatinine and potassium levels and HbA1c. Angiotensin receptor blocker and albuminuria T Okura et al Statistics All analyses were performed using StatView 5.0 (SAS Institute, Cary, NC, USA). Data in the text and the tables are expressed as the mean±s.d. except for urinary albumin. Differences between two groups with a normal distribution were compared by unpaired Student's t-tests. The Wilcoxon rank-sum test was applied where appropriate. Yates-corrected w 2 -test was used for comparisons between categorical data (gender and current smoking). Univariate linear regression analysis was performed in order to investigate the relationship between changes in BP and urinary albumin. Po0.05 was considered significant.
In a previous pilot study using a cross-over design and identical dosage regimes to the current study, the average difference in the reduction of urinary albumin between the two protocols in each patient was 19.7 ± 24.8%. The absolute changes in BP from baseline were 7.3±6.2/0.7±3.9 mm Hg and 8.7 ± 8.0/0.7 ± 1.6 mm Hg after up-titration and combination therapy, respectively. Based on these findings, the difference in urinary albumin excretion from baseline following the therapeutic regimes used in the current study was expected to be 20 ± 25%. To achieve a power of 80% with a twosided test of significance at a ¼ 0.05, 25 patients were required in each arm of the study to demonstrate the superiority of titration therapy. To account for possible patient withdrawal from the study, we planned to recruit 30 patients to each group.
Results
At the time of baseline evaluation, 2 of 60 patients were excluded from the study because their BP was below 130/80 mm Hg, whereas the remaining patients (n ¼ 58) were randomized to either the uptitration or combination treatment groups. Patient characteristics at baseline are given in Table 1 . The mean age and BP of all 58 patients at baseline were 58.5±10.3 years and 139.3±8.3/80.4±6.1 mm Hg, respectively. All patients had detectable albuminuria ranging from 15.1 to 709.3 mg g À1 creatinine (median 72.0 mg g À1 creatinine). Although there were significantly more men in the up-titration compared with the combination therapy group, there were no significant differences in other background parameters between the two groups ( Table 1) .
Both up-titration of candesartan from 8 to 12 mg daily and combination treatment with candesartan plus amlodipine effectively reduced BP (Figure 2 ). Additional anti-hypertensive drugs were prescribed to eight patients in the up-titration group; six patients were additionally prescribed 2.5 mg amlodipine and another two patients 1 mg indapamide. Similarly, 14 patients in the combination group had additional anti-hypertensive drugs prescribed; eight with 2.5 mg amlodipine, two with 5 mg amlodipine, and four with 1 mg indapamide. There was no significant difference in BP between the two groups throughout the study period. Furthermore, there was no significant difference in the reduction in BP between the up-titration (DSBP/DDBP À11.0/ À0.8 mm Hg; mean BP À3.1 mm Hg) and combination (DSBP/DDBP À8.7/À1.6 mm Hg; mean BP À2.3 mm Hg; NS) groups.
Urinary excretion of albumin was reduced in both the up-titration and combination groups (Figure 3) . However, the reduction was much greater in the uptitration group (41.5 ± 14.3%) than in the combination group (9.2±37.6%; Po0.0001). Although there was a correlation between the reduction in urinary albumin excretion and SBP in the combination group, a similar correlation was not observed in the up-titrated group (Figure 4) .
Discussion
The present study demonstrated that up-titration of the candesartan dose may more effectively reduce urinary albumin excretion for the same level of BP achieved and the same degree of BP reduction, than does the combination treatment with candesartan plus amlodipine in T2DM patients with albuminuria, who are being treated with a standard dose of candesartan. The renoprotective effect of candesartan is greater than that expected based on the reduction in BP alone.
The development of albuminuria in T2DM increases the risk of renal and cardiovascular disease. 24, 25 Conversely, a reduction in albuminuria during anti-hypertensive treatment is associated with a diminished rate of decline in the glomerular filtration rate and an improvement in the renal, 26, 27 Angiotensin receptor blocker and albuminuria T Okura et al and possibly cardiovascular, prognosis. 28 Thus, albuminuria is now considered the most important surrogate end-point in the management of diabetic patients, with the aim of preventing diabetic nephropathy 29, 30 and cardiovascular events. Control of BP and RAS blockade are key in the management of diabetic patients with albuminuria. Indeed, trials in T2DM patients with albuminuria demonstrated a renoprotective effect of angiotensin converting enzyme inhibitors or ARBs. 19, 31, 32 In most cases, RAS inhibitors alone cannot lower BP to target levels and combination treatment with different classes of antihypertensive drugs or up-titration of RAS inhibitors are often required. However, no trial has demonstrated which strategy is better in terms of renoprotection for the same degree of BP reduction. The present study provides clear evidence that uptitration of an ARB is better than the combination treatment with the ARB plus a calcium channel blocker in reducing the urinary excretion of albumin. However, the present study also confirmed that lowering BP itself has a renoprotective effect, because the addition of amlodipine to the standard dose of candesartan reduced urinary excretion of albumin in a BP-dependent manner. Although several reports suggest that calcium channel blockers lower urinary albumin excretion through a systemic BP-dependent mechanism, 33,34 this effect was not confirmed in the MARVAL study, 13 in which treatment with amlodipine for 12 weeks did not lower the urinary excretion of albumin in diabetic patients with microalbuminuria. Because the present study was performed in patients taking candesartan, blockade of the RAS may unmask the pressure-dependent renoprotective effects of amlodipine. Alternatively, inhibition of the RAS may be necessary for amlodipine to exert its BP-dependent effect on the urinary excretion of albumin, at least over the relatively short duration of anti-hypertensive therapy.
There was no significant difference in BP between the two groups throughout the study period, and the reduction in BP was comparable after uptitration of candesartan and the addition of amlodipine. It should be noted that, in the present study, only the combination group showed a BP-dependent reduction in albuminuria. Conversely, in the uptitration group, there was no significant relationship between changes in BP and urinary albumin excretion. Thus, in contrast with the effect of amlodipine, up-titration of candesartan reduced urinary albumin excretion independent of the effects on BP. The renoprotective effects of candesartan may involve a reduction in glomerular capillary pressure caused by dilatation of efferent arteries, changes in glomerular capillary wall permeability, tissue remodeling and beneficial effects on nephrin in the glomeruli. These effects of candesartan on kidney function may be independent of its effects on BP, at least for doses titrated above the standard dose used.
Although albuminuria in this patient population is an independent risk factor for both end-stage renal disease and cardiovascular disease, the present study was of a relatively short duration and we, therefore, cannot deduce whether the correction of albuminuria following up-titration of candesartan will translate into a reduction in cardiovascular events. Thus, a longer trial on a greater number of patients is needed before definite conclusions can be made that up-titration of candesartan has bene- Angiotensin receptor blocker and albuminuria T Okura et al ficial effects on renal and cardiovascular outcomes, compared with the addition of amlodipine for the same level of BP achieved and the same degree of BP reduction.
Interpretation of the data may be affected by the following points. First, the open label nature of the present study's protocol may have introduced some bias. Second, there was a non-significant difference in the reduction of BP between the up-titration and the combination groups, and this may partially contribute to the beneficial effects noted in the uptitration group.
In conclusion, up-titration of the dose of candesartan is more effective than the combination treatment with candesartan plus amlodipine in patients with T2DM and albuminuria, following initial treatment with a standard dose of candesartan for the same level of BP achieved and the same degree of BP reduction. This renal effect of candesartan is greater than that expected from its effects in reducing BP alone.
